Shahrokh Shariat is Professor and Director of the University Clinic of Urology at the Medical University of Vienna, Vienna General Hospital. He is also Assistant Professor of Urology and Oncology at Weill Cornell Medical Center in New York and Assistant Professor of Urology at the University of Texas Southwestern in Dallas, Charles University Medical School in Prague and Setschenow University in Moscow.
Professor Shariat has published more than 1100 scientific articles in peer-reviewed journals (Scopus h-index: 90 with 34563 citations; Google scholar h-index: 119 with 74204), more than 420 non-peer-reviewed publications, 18 book chapters, and a guidebook. Shariat holds 4 patents resulting from its research on prostate and bladder cancer. He has received numerous national and international awards: in 2014 he received the Matula Prize from the European Society of Urology (UAE), in 2017 the Gold Cystoscope Award from the American Society of Urology, probably the most important urologist award in the world.
Shariat is a leading member of several multi-centre research groups (Bladder Cancer Research Consortium, Bladder Cancer Detection Group and Urothelial Upper Tract Carcinoma Collaboration) and prospective clinical trials. He is a member of numerous academic societies and a reviewer for a scientific journal, for abstracts at meetings and for grants to national and international organizations. He is on the editorial board of journals such as European Urology, BJU International, World Journal of Urology, Current Opinion in Urology (editor-in-chief) and Immunotherapy. Shariat runs a charity for refugees and participates as a physician in two other charitable projects.
His scientific interest is in urological oncology – including molecular mechanisms and markers, early detection, research into the origin and therapy of diseases, translational studies and outcome research. In particular, Shariat is engaged in the discovery, testing and validation of molecular markers related to the biological and clinical properties of prostate and urothelial carcinomas. Laboratory projects focus on integrative genomics and epigenetics with the overall goal of developing individualized, i.e. personalized, therapies.
Search results up to December 2019:
– 1100 original peer-reviewed articles
– Scopus h-index: 90; number of citations: 34’563
– Google h-index: 119; Number of citations: 74’204
– 429 non-peer-reviewed publications
– 18 book chapters and a guide
– more than 1,000 abstracts for national and international symposia
– 4 patents; more than 80 national and international awards
– Member of 25 scientific societies
– Member of the editorial boards of 26 scientific journals
– Matula Award of the European Society of Urology (EAU)
– Golden Cystoscope Award of the American Society of Urology (AUA)